1938 related articles for article (PubMed ID: 16810614)
1. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
2. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
3. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
4. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
5. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
6. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
7. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
8. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
9. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
10. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
11. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
12. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
15. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
[TBL] [Abstract][Full Text] [Related]
16. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
17. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
[TBL] [Abstract][Full Text] [Related]
18. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
19. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
20. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
